Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Galvus (vildagliptin) - DPP-IV Inhibitor / Oral



Type 2 diabetes

Type 2 diabetes accounts for up to 95% of all cases of diabetes.

  • Diabetes management
    Management of type 2 diabetes requires the maintenance of good glycaemic...
  • Injectable insulins and oral antidiabetic medications
    A range of injectable insulins and oral antidiabetic medications are used in...
  • Blood pressure and obesity
    Raised blood pressure and obesity are features common to people who develop...
  • Type 2 diabetes
    Type 2 diabetes accounts for up to 95% of all cases of diabetes.
  • Diabetes estimates
    Current estimates indicate that worldwide about 170 million people suffer...

Back to Project Details



Related Projects

Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

Exanta - Oral Direct Thrombin Inhibitor for the
Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI)...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

See all projects


Follow Us:
Twitter Twitter    Facebook Facebook   
Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2012 Net Resources International, a trading division of SPG Media Limited.